Ablation Clinical Trials in Beijing, None Selected
3 recruitingBeijing, None Selected, China
Showing 1–3 of 3 trials
Recruiting
Not Applicable
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Hepatocellular CarcinomaRecurrent TumorMicrowave Ablation+1 more
Sun Yat-sen University108 enrolled1 locationNCT06609876
Recruiting
Not Applicable
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
AblationSystemic TherapyRecurrent Hepatocellular Carcinoma+2 more
Sun Yat-sen University116 enrolled1 locationNCT06609850
Recruiting
Not Applicable
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University60 enrolled1 locationNCT06550921